ArticleCancer medicine2025
"I Missed My Other Oncologist": Established Relationships as Barriers and Facilitators to Accessing CAR-T and Autologous Transplantation.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Building Trust in a Newly Established Physician-Patient Relationship: A Scoping Review.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- "I Missed My Other Oncologist": Established Relationships as Barriers and Facilitators to Accessing CAR-T and Autologous Transplantation.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundAutologous stem cell transplantation (ASCT) and chimeric antigen receptor T-cell therapy (CAR-T) can provide significant clinical benefit, but are not equally available to all patients. Oncologist continuity and trust are important to patients, and may act as barriers to receipt of therapy. However, detailed data are lacking on the mechanism by which these might affect receipt of therapy, or how this barrier may be overcome.
methodsWe conducted a qualitative interview study with patients with non-Hodgkin lymphoma (NHL), classic Hodgkin lymphoma (cHL) or multiple myeloma (MM) eligible for or treated with ASCT/CAR-T. Participants were recruited from a multi-site academic health system that includes a safety net hospital considered to be one of the most racially inclusive in the country. Interviews were independently coded by two trained coders.
resultsForty patients participated. Half were female, 65% had multiple myeloma, 45% identified as Black or African American, 22.5% had an income less than $30,000 and 33% were insured with Medicaid. In addition to treatment-specific factors and logistical factors such as housing and transportation, patients identified the need to establish care and trust with a new provider as potential barriers to receipt of therapy. This process could be facilitated by the perception of strong communication and existing relationships between patients' established and new providers.
conclusionsIn addition to logistical and clinical factors, several factors centering around existing and newly required patient-provider relationships may influence patients' acceptance of ASCT/CAR-T. Acceptance may be enhanced by addressing relationship-based barriers in a manner that emphasizes continuity and helps build trust with a new provider, such as by explicitly demonstrating seamless communication among care teams.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.